Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Emergent BioSolutions Inc.NYSE: EBS

Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other non-current liabilities rises 17.8% from a year ago

Other non-current liabilities stood at $41.7M at the end of Q1 FY2026, up 17.8% from a year earlier and down 22.6% from the prior quarter. Over 3 fiscal years it compounded at +26.4% a year.

Context

  • Other non-current liabilities amounted to 3.2% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
  • Other non-current liabilities increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +17.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$41.7M-22.6% QoQ
Last fiscal yearDec 2025
$53.9M+83.3% YoY
Year agoMar 2025
$35.4M+17.8% since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.8%——
1 year+83.3%——
3-year CAGR+26.4%——
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
53.9M USD
Year-over-year change
+83.3%
4-year CAGR
+7.3%

Other Non-current Liabilities vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +17.8% is the 2nd highest of 8, against a peer median of -29.8%.
  • Other non-current liabilities amounts to 3.2% of total assets for EBS, versus a peer median of 0.5%.
EBS Competitors
Other Non-current Liabilities for EBS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CMPSCOMPASS Pathways plcMar 2026$50.48M USD-29.8%—9.5%
EBSEmergent BioSolutions Inc.Mar 2026$41.7M USD+17.8%+26.4%3.2%
ESPREsperion Therapeutics, Inc.Mar 2026$8.74M USD-96.3%-65.8%1.9%
SNDLSNDL Inc.Mar 2026CA$6.92M CAD+11.1%+43.8%0.5%
AQSTAquestive Therapeutics, Inc.Mar 2026$6.05M USD-93.0%-52.1%4.3%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$3M USD——0.6%
SIGASIGA Technologies, Inc.Mar 2026$2.51M USD-20.0%-7.6%1.1%
ORGOOrganogenesis Holdings Inc.Mar 2026$1.49M USD+65.7%—0.3%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$0 USD——0.0%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$0 USD-100.0%—0.0%
PRTAProthena Corporation plcMar 2026$0 USD——0.0%
Peer median (excluding EBS) —-29.8%-29.8%0.5%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents576.3M642.6M111.7M99.5M205.4M
Short-term Investments00000
Net Receivables278.9M159.2M191M154.5M84.2M
Inventory344.5M350.7M328.9M311.7M343.4M
Other Current Assets70.2M57.9M47.9M33M29.5M
Total Current Assets1.27B1.21B679.5M598.7M662.5M
Property, Plant & Equipment (Net)828.4M837M399M270.6M205.4M
Goodwill224.9M218.2M000
Intangible Assets604.6M728.8M566.6M501.5M436.5M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets29.9M171.9M178.1M18.9M14.2M
Total Non-current Assets1.69B1.96B1.14B791M656.1M
Total Assets2.96B3.17B1.82B1.39B1.32B
Account Payables128.9M103.5M112.2M60.9M55.6M
Short-term Debt37.4M963.1M413.7M2.7M0
Tax Payables00000
Deferred Revenue11.7M26.4M000
Other Current Liabilities107.3M48.6M106.8M81.1M76.6M
Total Current Liabilities374M1.23B651.3M162.4M132.2M
Long-term Debt809.4M448.5M446.5M663.7M572.1M
Deferred Tax Liabilities93.3M59.7M47.2M41.7M37.8M
Deferred Revenue (Non-current)4.7M0000
Other Non-current Liabilities40.6M26.7M28.9M29.4M53.9M
Total Non-current Liabilities972.2M549.7M522.6M744.5M663.8M
Total Liabilities1.35B1.78B1.17B906.9M796M
Common Stock100K100K100K100K100K
Retained Earnings950.3M738.7M(21.8M)(212.4M)(159.8M)
Accumulated OCI(16.1M)3.1M(5.7M)(5.2M)(7.5M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.61B1.39B649.3M482.8M522.6M
Total Debt871M1.43B860.2M676.1M572.1M
Net Debt294.7M783.8M748.5M576.6M366.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.